Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.
2.

NMDA receptor hypofunction model of schizophrenia.

Olney JW, Newcomer JW, Farber NB.

J Psychiatr Res. 1999 Nov-Dec;33(6):523-33. Review.

PMID:
10628529
3.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
4.
5.

Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Gaspar PA, Bustamante ML, Silva H, Aboitiz F.

J Neurochem. 2009 Nov;111(4):891-900. doi: 10.1111/j.1471-4159.2009.06325.x. Epub 2009 Aug 4. Review.

6.

Computational models of schizophrenia and dopamine modulation in the prefrontal cortex.

Rolls ET, Loh M, Deco G, Winterer G.

Nat Rev Neurosci. 2008 Sep;9(9):696-709. doi: 10.1038/nrn2462. Review.

PMID:
18714326
7.

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.

Laruelle M, Kegeles LS, Abi-Dargham A.

Ann N Y Acad Sci. 2003 Nov;1003:138-58. Review.

PMID:
14684442
8.

Pathophysiologically based treatment interventions in schizophrenia.

Lewis DA, Gonzalez-Burgos G.

Nat Med. 2006 Sep;12(9):1016-22. Review.

PMID:
16960576
9.

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A.

Clin Ther. 2005;27 Suppl A:S16-24. Review.

PMID:
16198197
10.

Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.

Tsai SJ.

Med Sci Monit. 2005 Sep;11(9):HY39-45. Epub 2005 Aug 26. Review.

PMID:
16127367
11.

N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.

Domino EF, Mirzoyan D, Tsukada H.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):801-11. Review.

PMID:
15363604
12.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
13.

Direct and indirect modulation of the N-methyl D-aspartate receptor.

Marino MJ, Conn PJ.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16. Review.

PMID:
12769631
14.

[Glutamatergic hypothesis of schizophrenia].

Bressan RA, Pilowsky LS.

Rev Bras Psiquiatr. 2003 Sep;25(3):177-83. Review. Portuguese.

15.

Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.

du Bois TM, Huang XF.

Brain Res Rev. 2007 Feb;53(2):260-70. Epub 2006 Oct 2. Review.

PMID:
17014910
16.
17.

Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity.

Arundine M, Tymianski M.

Cell Calcium. 2003 Oct-Nov;34(4-5):325-37. Review.

PMID:
12909079
18.

Advances in schizophrenia.

Thaker GK, Carpenter WT Jr.

Nat Med. 2001 Jun;7(6):667-71. Review.

PMID:
11385502
19.

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.

Chavez-Noriega LE, Schaffhauser H, Campbell UC.

Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):261-81. Review.

PMID:
12769619
20.

Gene-environment interplay in schizopsychotic disorders.

Palomo T, Archer T, Kostrzewa RM, Beninger RJ.

Neurotox Res. 2004;6(1):1-9. Review.

PMID:
15184100
Items per page

Supplemental Content

Write to the Help Desk